ASCO, NCCN, MASCC/ESMO: a Comparison of Antiemetic Guidelines for the Treatment of Chemotherapy-induced Nausea and Vomiting in Adult Patients

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2018 Oct 5

PMID 30284039

Citations 59

Authors

Yasmeen Razvi

Stephanie Chan

Thomas McFarlane

Erin McKenzie

Pearl Zaki

Carlo DeAngelis

William Pidduck

Ahmad Bushehri

Edward Chow

Katarzyna Joanna Jerzak

Affiliations

Soon will be listed here.

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with a variety of early- and end-stage malignancies. In light of recent changes in the optimal management of CINV, we undertook this narrative review to compare the latest guidelines published by ASCO (2017), NCCN (2018), and MASCC/ESMO (2016). The processes undertaken by each organization to evaluate existing literature were also described. Although ASCO, NCCN, and MASCC/ESMO guidelines for the treatment and prevention of CINV share many fundamental similarities, literature surrounding low and minimal emetic risk regimens is lacking. Data regarding the use of complementary alternative medicine for CINV is particularly scarce and in need of further investigation.

Citing Articles

Evaluation of chemotherapy-induced nausea and vomiting in low, moderate, and highly emetogenic schemes between sexes.

Albanell-Fernandez M, Rodriguez Mues M, Figueras C, Altamirano M, Monge-Escartin I, Riu-Viladoms G Support Care Cancer. 2025; 33(4):261.

PMID: 40064679 PMC: 11893662. DOI: 10.1007/s00520-025-09319-7.

Effects of mindfulness-based stress reduction on cancer-related fatigue in patients with breast cancer: a meta-analysis of randomized controlled trials.

Lan X, Xie H, Fu L, Peng W Front Oncol. 2024; 14:1425563.

PMID: 39421452 PMC: 11484075. DOI: 10.3389/fonc.2024.1425563.

Comparative effectiveness of netupitant-palonosetron plus dexamethasone versus aprepitant-based regimens in mitigating chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials.

Luo W, Chang C, Huang T, Gautama M Oncologist. 2024; 30(2).

PMID: 39284781 PMC: 11886791. DOI: 10.1093/oncolo/oyae233.

Establishing a nausea-free ward model to reduce chemotherapy-induced nausea and vomiting: A retrospective study.

Wang Y, Deng M, Huang Y, Liu L, Xiao Y, Hu L Medicine (Baltimore). 2024; 103(22):e38357.

PMID: 39259117 PMC: 11142820. DOI: 10.1097/MD.0000000000038357.

Symptom clusters and network analysis of patients with intermediate and advanced liver cancer treated with targeted immunotherapy.

Chen M, Li S, Jin G, Li R, Qi Z, He Y Support Care Cancer. 2024; 32(9):580.

PMID: 39115725 DOI: 10.1007/s00520-024-08784-w.

References

Hesketh P, Kris M, Basch E, Bohlke K, Barbour S, Clark-Snow R . Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(28):3240-3261. DOI: 10.1200/JCO.2017.74.4789. View

Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M . Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol. 2013; 32(2):101-6. DOI: 10.1200/JCO.2013.51.4547. View

Aapro M, Rugo H, Rossi G, Rizzi G, Borroni M, Bondarenko I . A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014; 25(7):1328-1333. PMC: 4071754. DOI: 10.1093/annonc/mdu101. View

Navari R, Nagy C, Gray S . The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013; 21(6):1655-63. DOI: 10.1007/s00520-012-1710-6. View

Navari R, Qin R, Ruddy K, Liu H, Powell S, Bajaj M . Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016; 375(2):134-42. PMC: 5344450. DOI: 10.1056/NEJMoa1515725. View

Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L . Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Ann Oncol. 2015; 26(6):1248-1253. DOI: 10.1093/annonc/mdv132. View

Bruce K, Hall L, Castelo S, Evans M, Frangoul H . Direct provider feedback to decrease chemotherapy ordering errors: the "gray envelope" initiative. Pediatr Blood Cancer. 2012; 59(7):1330-1. DOI: 10.1002/pbc.24224. View

Rithirangsriroj K, Manchana T, Akkayagorn L . Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients. Gynecol Oncol. 2014; 136(1):82-6. DOI: 10.1016/j.ygyno.2014.10.025. View

Pergam S, Woodfield M, Lee C, Cheng G, Baker K, Marquis S . Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use. Cancer. 2017; 123(22):4488-4497. PMC: 5698756. DOI: 10.1002/cncr.30879. View

10.

Weinstein C, Jordan K, Green S, Camacho E, Khanani S, Beckford-Brathwaite E . Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol. 2015; 27(1):172-8. PMC: 4684151. DOI: 10.1093/annonc/mdv482. View

11.

Matzka M, Kock-Hodi S, Jahn P, Mayer H . Relationship among symptom clusters, quality of life, and treatment-specific optimism in patients with cancer. Support Care Cancer. 2018; 26(8):2685-2693. PMC: 6018574. DOI: 10.1007/s00520-018-4102-8. View

12.

Griffin A, Butow P, Coates A, Childs A, Ellis P, Dunn S . On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996; 7(2):189-95. DOI: 10.1093/oxfordjournals.annonc.a010548. View

13.

Smith L, Azariah F, Lavender V, Stoner N, Bettiol S . Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev. 2015; (11):CD009464. PMC: 6931414. DOI: 10.1002/14651858.CD009464.pub2. View

14.

Vardy J, Chiew K, Galica J, Pond G, Tannock I . Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 2006; 94(7):1011-5. PMC: 2361221. DOI: 10.1038/sj.bjc.6603048. View

15.

Navari R . Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int. 2015; 2015:595894. PMC: 4573228. DOI: 10.1155/2015/595894. View

16.

Hickok J, Roscoe J, Morrow G, Bole C, Zhao H, Hoelzer K . 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol. 2005; 6(10):765-72. PMC: 1646426. DOI: 10.1016/S1470-2045(05)70325-9. View

17.

Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H . Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. Int J Clin Oncol. 2016; 22(2):405-412. DOI: 10.1007/s10147-016-1069-7. View

18.

Mertens W, Higby D, Brown D, Parisi R, Fitzgerald J, Benjamin E . Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol. 2003; 21(7):1373-8. DOI: 10.1200/JCO.2003.08.118. View

19.

Hesketh P, Schnadig I, Schwartzberg L, Modiano M, Jordan K, Arora S . Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer. 2016; 122(15):2418-25. PMC: 5084806. DOI: 10.1002/cncr.30054. View

20.

Coates A, Abraham S, Kaye S, Sowerbutts T, Frewin C, Fox R . On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983; 19(2):203-8. DOI: 10.1016/0277-5379(83)90418-2. View